Drug Profile
Desvenlafaxine - Pfizer
Alternative Names: Desvenlafaxine hydrochloride; Desvenlafaxine SR; Desvenlafaxine succinate; Desvenlafaxine succinate sustained release; Desvenlafaxine sustained-release; Desvenlaflaxine extended release; DVS-233; DVS-233 SR; DVS-SR; MD-120; O-desmethylvenlafaxine; Pristiq; WY-45233Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Jiangsu Hansoh Pharmaceutical; Pfizer; Wyeth
- Class Amines; Antidepressants; Cyclohexanols; Phenols; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Major depressive disorder; Vasomotor symptoms
- Discontinued Fibromyalgia; Neuropathic pain
Most Recent Events
- 14 Sep 2022 Mochida Pharmaceutical and Pfizer completes the phase III trial in Major depressive disorders in Japan (PO) (NCT04345471)
- 12 May 2020 Mochida Pharmaceutical and Pfizer initiated a phase III trial in Major depressive disorders in Japan (PO) before May 2020 (NCT04345471)
- 17 Apr 2020 Mochida Pharmaceutical in collaboration with Pfizer plans a phase III trial for Major Depressive Disorder in Japan (PO) (NCT04345471)